What question did this study set out to answer?

To summarize the progress and recommendations regarding the use of Haemophilus influenzae type b polysaccharide vaccine in children.

March 22, 2026

Progress in Haemophilus Type b Polysaccharide Vaccine Use in the United States

Key Points

To summarize the progress and recommendations regarding the use of Haemophilus influenzae type b polysaccharide vaccine in children.
Licensing of the vaccine by the FDA in 1985.
Recommendations for routine use by health committees published shortly thereafter.
Distribution data of the vaccine assessed from licensure to July 1986.
Over 5 million doses of the vaccine were distributed in the United States by July 1986.
Routine usage was recommended for children starting at 24 months of age.

Abstract

In April 1985, the US FDA licensed Haemophilus influenzae type b polysaccharide vaccine to protect against invasive disease caused by H influenzae type b. Shortly thereafter, both the Immunization Practices Advisory Committee of the US Public Health Service1 and the Committee on Infectious Diseases of the American Academy of Pediatrics2 published recommendations for the routine use of this new vaccine in children at 24 months of age. More recently, updates of these recommendations have been published.3-5 From the date of vaccine licensure through July 1986, when the survey by Gururaj et al6 was conducted, more than 5 million doses of vaccine were distributed in the United States.

问 AI

Bookmark